A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001)

Inclusion Criteria: * Healthy males and females between 18 and 55 years (inclusive) of age. * Non-smoking (by declaration) for a period of at least 6 months. * Subjects able to adhere to the visit schedule and protocol requirements and be available to complete the study. * Haematology and Chemistry values within normal ranges or with no clinical significance * Subjects who provide written informed consent to participate in the study Exclusion Criteria: * Known history of significant medical disorder, which in the investigator's judgment contraindicates administration of the study medications. * Ongoing flu symptoms or influenza * Any clinically significant abnormality upon physical examination or in the clinical laboratory test at screening visit. * Treatment with immune immunosuppressant drugs or other immune enhancing drugs. * Subjects who have been immunized with anti-influenza vaccine or infected by influenza virus within one year prior to the screening visit. * Administration of any vaccine 30 days before the screening visit. * Known history of drug or alcohol abuse. * Known history of HIV, hepatitis C or B virus (HCV or HBV) * Subjects with known Guillain Barré Syndrome in the past * 2 or more hospitalization within the last year prior to screening visit * Increased liver enzymes 2.5 times above the upper reference level * Known hypersensitivity and/or allergy to any drugs * Any acute medical situation (e.g. acute infection) within 48 hours of study start, which is considered of significance by the Principal Investigator. * Subjects who participated in another clinical study within 30 days prior to study entry * Subjects who are non-cooperative or unwilling to sign consent form. * Pregnant or lactating women at entry to study and those that are unwilling to agree to continue precautions for two months after completion of the study